Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Chemosensitivity and p53; new tricks by an old dog.

Lønning PE, Knappskog S.

Breast Cancer Res. 2012 Nov 6;14(6):325. doi: 10.1186/bcr3326.

2.

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S.

Biochim Biophys Acta. 2013 Mar;1830(3):2790-7.

PMID:
23246812
3.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

4.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.

PMID:
24074787
5.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.

6.

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.

Cancer Res. 2001 Mar 15;61(6):2505-12.

7.

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G.

Cancer Cell. 2012 Jun 12;21(6):793-806. doi: 10.1016/j.ccr.2012.04.027.

8.

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H.

Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12.

9.

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.

Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE.

Nat Med. 1996 Jul;2(7):811-4.

PMID:
8673929
10.

WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.

Cuddihy AR, Jalali F, Coackley C, Bristow RG.

Mol Cancer Ther. 2008 Apr;7(4):980-92. doi: 10.1158/1535-7163.MCT-07-0471.

11.

Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.

Elmore LW, Di X, Dumur C, Holt SE, Gewirtz DA.

Clin Cancer Res. 2005 Apr 1;11(7):2637-43.

12.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.

13.

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.

Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A.

Oncogene. 2006 Jan 12;25(2):304-9.

PMID:
16170357
14.

Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.

Nestal de Moraes G, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP, Maia RC.

Eur J Cell Biol. 2013 Aug-Sep;92(8-9):247-56. doi: 10.1016/j.ejcb.2013.08.001. Epub 2013 Aug 31.

PMID:
24064045
15.

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE.

Eur J Cancer. 2003 Mar;39(4):438-46.

PMID:
12751373
16.

P53 and its molecular basis to chemoresistance in breast cancer.

Knappskog S, Lønning PE.

Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S23-30. doi: 10.1517/14728222.2011.640322. Epub 2012 Feb 8. Review.

PMID:
22313396
17.
18.

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P.

Int J Cancer. 2009 Feb 15;124(4):991-7. doi: 10.1002/ijc.24049.

19.

Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy.

Tikoo K, Sane MS, Gupta C.

Toxicol Appl Pharmacol. 2011 Mar 15;251(3):191-200. doi: 10.1016/j.taap.2010.12.012. Epub 2010 Dec 29.

PMID:
21194538
20.

p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours.

Guillot C, Falette N, Paperin MP, Courtois S, Gentil-Perret A, Treilleux I, Ozturk M, Puisieux A.

Oncogene. 1997 Jan 9;14(1):45-52.

Supplemental Content

Support Center